• IzoView Breast CT designed as the first breast-dedicated CT imaging system to eliminate tissue overlap and compression limitations specifically for breast cancer screening in patients with dense breast tissue
• Platform model supports multiple future clinical applications, including diagnosis and treatment planning without hardware replacement
• Regulatory pathway alignment and commercialization planning position Izotropic for potential market entry into a $8.7B global breast imaging sector

Imaging’s Stagnation Meets a New Wave of Purpose-Built Devices

For decades, breast cancer screening has relied heavily on mammography, a compression-based modality that, while valuable, carries persistent shortcomings. Dense breast tissue, which affects nearly half of women, often obscures lesions, leading to missed cancers or unnecessary callbacks. These limitations have fueled billions in annual healthcare costs tied to follow-up imaging and inconclusive results.

Against this backdrop, medical imaging technology has reached an inflection point. Artificial intelligence, high-resolution computational imaging, and patient-centered design are converging to open new possibilities. Dedicated systems built specifically for breast applications, rather than adapted from general diagnostic tools, are emerging to close critical gaps in cancer detection.

Izotropic (CSE: IZO) (OTCQB: IZOZF) is at the forefront of this transformation with its flagship IzoView Breast CT Imaging System, a technology designed to reimagine breast imaging from the ground up.

Purpose-Built to Overcome Structural Barriers

IzoView departs from legacy 2D imaging by offering true 360-degree, three-dimensional visualization of the breast without compression. The architecture eliminates the masking effect caused by overlapping tissue, a problem particularly acute in dense breasts, while delivering spatial resolution orders of magnitude higher than MRI at a fraction of the cost.

The device has been engineered with workflow and patient experience in mind. A ten-second scan provides comprehensive imaging, compared with MRI procedures that can last more than an hour. Radiation levels are comparable to standard two-view mammography, further supporting patient safety and clinical acceptance.

By specifically addressing structural barriers inherent to mammography and partial-angle 3D modalities, IzoView represents a dedicated, single-modality solution capable of consolidating diagnostic steps that often stretch across mammography, ultrasound, and MRI.

Scalable Value Through a Platform Approach

A distinguishing feature of Izotropic’s design philosophy is its platform-based model. Instead of serving as a static piece of equipment, IzoView is built for expansion through software upgrades, not hardware replacement.

The company has identified at least 14 future clinical applications that can be supported by the system, ranging from screening and diagnosis to treatment planning and monitoring. This flexibility allows healthcare providers to expand capabilities over time while maximizing return on investment, a key factor in technological adoption in cost-conscious hospital systems.

Additionally, IzoView integrates self-shielding radiation containment, removing the need for specialized facility retrofits. This design choice lowers installation barriers and broadens accessibility across a wider range of imaging centers.

Market and Regulatory Positioning

The breast imaging device market is projected to grow from $5.4 billion in 2024 to $8.7 billion by 2030, reflecting increasing demand for precision diagnostic tools and advanced modalities. Within this market, demand is particularly strong in dense breast imaging, a segment where IzoView directly addresses existing limitations.

Izotropic has achieved alignment with the U.S. Food and Drug Administration on its regulatory pathway, a milestone that reduces uncertainty around clinical trial design and eventual approval requirements. The company has also completed a detailed strategic business plan and commercialization roadmap, underscoring preparation for entry into U.S. and international markets.

To complement regulatory progress, Izotropic has invested in awareness-building initiatives, including the dedicated BreastCT.com platform and a podcast series designed to educate clinicians, patients, and investors about the advantages of breast-dedicated CT imaging.

Positioned for Transformation

Izotropic’s strategy combines technical differentiation, competitive economics, and scalable growth potential in a market urgently seeking better solutions. By addressing the shortcomings of mammography, ultrasound, and MRI with a purpose-built system, the company is positioned to compete not only on performance but also on workflow efficiency and cost-effectiveness.

If successful, IzoView could mark a turning point in breast cancer detection, one that shifts the paradigm toward faster, more accurate, and more accessible imaging. For healthcare systems under pressure to deliver better outcomes while controlling costs, such a solution could represent both a clinical and economic breakthrough.

For more information, visit the company’s website at www.IzoCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN